Relationship of the SAMe-TT2R2score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation

Chest

Volumn 146, Issue 3, 2014, Pages 719-726

  Lip, Gregory Y H ^a   Haguenoer, Ken ^b   Saint Etienne, Christophe ^b   Fauchier, Laurent ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART TAMPONADE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; SCORING SYSTEM; SMOKING; THROMBOEMBOLISM; ADULT; AGE; ANCESTRY GROUP; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; COHORT ANALYSIS; DRUG INTERACTION; FOLLOW UP; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; SURVIVAL RATE; TOBACCO USE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; COHORT STUDIES; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEX FACTORS; STROKE; SURVIVAL RATE; TOBACCO USE; TREATMENT OUTCOME; VITAMIN K;

EID: 84901644405     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2976     Document Type: Article

References (13)

1. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011; 106 (5): 968-977.
2. Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013; 110 (6): 1189-1198.
3. De Caterina R, Husted S, Wallentin L, et al; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 109 (4): 569-579.
4. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110 (6): 1087-1107.
5. Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. Best Pract Res Clin Haematol. 2013; 26 (2): 115-129.
6. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2 R2 score. Chest. 2013; 144 (5): 1555-1563.
7. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol. 2012; 5 (5): 941-948.
8. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifi cation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285 (22): 2864-2870.
9. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refi ning clinical risk stratifi cation for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137 (2): 263-272.
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138 (5): 1093-1100.
11. Boriani G. Predicting the quality of anticoagulation during warfarin therapy: the basis for an individualized approach. Chest. 2013; 144 (5): 1437-1438.
12. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013; 34 (14): 1041-1049.
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69 (3): 236-239.